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Laparoscopic treatment of isolated
superficial peritoneal endometriosis for
managing chronic pelvic pain in women:
study protocol for a randomised controlled
feasibility trial (ESPriT1)
Lucy H. R. Whitaker1, Ann Doust1, Jacqueline Stephen2, John Norrie2, Kevin Cooper3, Jane Daniels4,
Lone Hummelshoj5, Emma Cox6, Laura Beatty7, Patrick Chien8, Mayank Madhra9, Katy Vincent10
and Andrew W. Horne1*
Abstract
Background: Endometriosis (where endometrial-like tissue is found outside the uterus) affects ~ 176 million
women worldwide and can lead to debilitating pelvic pain. Three subtypes of endometriosis exist, with ~ 80% of
women having superficial peritoneal endometriosis (SPE). Endometriosis is diagnosed by laparoscopy and, if SPE is
found, gynaecologists usually remove it surgically. However, many women get limited pain relief from surgical
removal of SPE. We plan to undertake a future large trial where women who have only SPE found at initial
laparoscopy are randomly allocated to have surgical removal (excision or ablation) of SPE, or not. Ultimately, we
want to determine whether surgical removal improves overall symptoms and quality of life, or whether surgery is of
no benefit, exacerbates symptoms, or even causes harm. The primary objective of this feasibility study is to
determine what proportion of women with suspected SPE undergoing diagnostic laparoscopy will agree to
randomisation. The secondary objectives are to determine if there are differences in key prognostic parameters
between eligible women that agree to be randomised and those that decline; how many women having
laparoscopy for investigation of chronic pelvic pain are eligible for the trial; the range of treatment effects and
variability in outcomes and the most acceptable methods of recruitment, randomisation and assessment tools.
Methods: We will recruit up to 90 women with suspected SPE undergoing diagnostic laparoscopy over a 9-month
recruitment period in four Scottish hospitals and randomise them 1:1 to either diagnostic laparoscopy alone (with a
sham port to achieve blinding of the allocation) or surgical removal of endometriosis. Baseline characteristics, e.g.
age, index of social deprivation, ethnicity, and intensity/duration of pain will be collected. Participants will be
followed up by online questionnaires assessing pain, physical and emotional function at baseline, 3 months, 6
months and 12 months.
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Discussion: Recruitment to a randomised controlled trial to assess the effectiveness of surgery for endometriosis
may be challenging because of preconceived ideas about treatment success amongst patients and clinicians. We
have designed this study to assess feasibility of recruitment and to inform the design of our future definitive trial.
Trial registration: ClincicalTrials.gov, NCT04081532
Status: Recruiting
Keywords: Chronic pelvic pain, Surgery, Excision, Ablation, Feasibility trial, Placebo
Background
Endometriosis is a chronic oestrogen-dependent condi-
tion that affects an estimated 176 million women world-
wide [1]. It is defined by the presence of endometrial-
like tissue (‘lesions’) outside the uterus [2]. It is now gen-
erally accepted that there are three endometriosis sub-
types (‘superficial peritoneal’ or ‘SPE’, ‘ovarian’, and
‘deep’). Endometriosis is associated with debilitating pel-
vic pain and/or infertility and the socioeconomic costs
of endometriosis in the UK are ~ £8.2 billion per year
with direct healthcare costs amounting to ~ £2315 per
woman per year (based on 2009 prices), similar to those
of diabetes mellitus [3].
Management options in current national and inter-
national endometriosis guidelines for women with
endometriosis-associated pelvic pain include surgical
removal of endometriosis and medical treatment
with analgesics, ovarian suppressive drugs, and neu-
romodulators [4, 5]. ‘Surgical removal’ involves lap-
aroscopic excision and/or ablation of the
endometriosis, often undertaken at the time of initial
laparoscopy to investigate pelvic pain. Establishing
whether treating isolated SPE in women with chronic
pelvic pain is clinically and cost-effective is import-
ant because this forms a large part of the workload
in gynaecology and uses considerable resources.
Around 30% of the direct health care costs of endo-
metriosis are attributable to the cost of surgical
treatment. Data from Scotland (population: 5.3 mil-
lion, 51% women) indicate that 101,137 pelvic lapar-
oscopies were performed in women from 1981 to
2010 [6]. An estimated 91,023 (90%) of these proce-
dures were for investigation of chronic pelvic pain
and, of these, 17,834 (20%) revealed a new diagnosis
of endometriosis. Half of the women with endomet-
riosis in this population underwent a further surgical
procedure for this condition within 5 years.
There is little scientific evidence to demonstrate
whether surgical removal of isolated SPE (accounting for
~ 80% of the subtypes) improves overall symptoms and
quality of life more than not surgically treating the endo-
metriosis, or whether surgery could exacerbate symp-
toms (or even cause harm). In the most recent Cochrane
review of ‘laparoscopic surgery for endometriosis’, the
authors conclude that laparoscopic removal improves
‘condition-associated pain’ (cited as ‘better’ or im-
proved’) compared to diagnostic laparoscopy alone at 6
months (OR 6.58, 95% CI 3.31 to 13.10) [7]. Yet, this
conclusion is based on data from only three randomised
controlled trials (RCT), only one of which blinded the
participants to their allocation, with a total of just 171
participants as well as an amalgam of different subtypes
of endometriosis. Furthermore, only one unblinded RCT
included in the analysis (just 69 participants) has follow-
up data to 12 months showing benefit of surgery (OR
10.00, 95% CI 3.21 to 31.17), leading the authors to de-
fine the strength of the evidence as of moderate and low
quality, respectively, for the two timepoints, using
GRADE criteria [8]. Furthermore, the uncertainty
around surgical management of SPE is compounded by
the limited evidence to allow an informed selection of
specific surgical modalities to remove SPE, e.g. laparo-
scopic ‘ablation’ versus laparoscopic ‘excision’) [9].
Consequently, the 2017 NICE Endometriosis Guideline
recommends further research into the effectiveness of
laparoscopic removal of SPE in isolation to manage
endometriosis-associated pain [10]. This research rec-
ommendation is also supported by the results of a recent
UK and Ireland James Lind Alliance Priority Setting
Partnership (PSP) Initiative for Endometriosis estab-
lished to identify the key research questions that were
most important to both women with endometriosis and
healthcare practitioners involved in their care [9].
If future research demonstrates that surgery is not ef-
fective for the treatment of pain associated with isolated
superficial peritoneal disease, it is possible that this
group of women could be spared an invasive surgical
procedure, in particular if their pelvic imaging does not
reveal any pathology (pelvic ultrasound or MRI, inter-
preted by an experienced operator, will diagnose ovarian
and deep endometriosis subtypes). They could instead
be offered investigations for other known causes of pel-
vic pain and early pain management (e.g. neuromodula-
tor drugs, physiotherapy, and psychological approaches).
Furthermore, it is conceivable that future research might
demonstrate that surgery for SPE in isolation is not only
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ineffective, but may aggravate the symptoms of pain, or
even cause harm. It is therefore crucial that policy-
makers, funding bodies, researchers, clinicians, and
women with endometriosis work together in a ‘precision
medicine ecosystem’ to build a knowledge base that can
determine whether SPE is better suited to surgical, con-
servative, or multimodal treatment to ultimately guide
and improve individualised patient care.
We believe that a large multicentre high-quality RCT is
urgently needed to determine whether laparoscopic exci-
sion/ablation is of clinical benefit to women with chronic
pelvic pain where the only finding is SPE. The aim of this
proposed blinded randomised study is to inform the feasi-
bility and design of this future large multicentre RCT.
Primary objective
The primary objective is to determine what proportion
of women with suspected SPE undergoing diagnostic
laparoscopy will agree to randomisation to either surgi-
cal removal of SPE or diagnostic laparoscopy alone.
Secondary objectives
1. To determine if there are any differences in
key prognostic parameters (including age,
social deprivation, ethnicity, and duration of
pain) between eligible women that agree to be
randomised and those that decline
participation.
2. To determine how many women having
laparoscopy for investigation of chronic pelvic pain
are eligible for the trial (i.e. have only SPE).
3. To determine the variability in outcomes.
4. To determine the most acceptable methods of
recruitment, randomisation, and assessment tools.
Methods/design
Study design
We aim to perform a two-arm, parallel, double-blind
randomised controlled feasibility trial (Fig. 1).
Fig. 1 Flow chart for the trial process
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Study settings
We will recruit patients from gynaecology outpatient
clinics, gynaecology wards, and day surgery units within
NHS Lothian (Royal Infirmary of Edinburgh and St
John’s Hospital), NHS Grampian (Aberdeen Royal In-
firmary), NHS Tayside (Ninewells Hospital) and NHS
Greater Glasgow and Clyde (Queen Elizabeth University
Hospital, Victoria Infirmary, Glasgow Royal Infirmary
and Stobhill Hospital) (all UK).
Study participants
Women with suspected SPE will be recruited prior to in-
vestigation by diagnostic laparoscopy.
Inclusion criteria
Women are eligible for inclusion if they are as follows:
 Aged between 18 and 55
 Undergoing laparoscopy for the investigation of
chronic pelvic pain
 Found to have isolated SPE identified at laparoscopy
(macroscopically)
 Able to give informed consent
Exclusion criteria
Women are excluded if they have one or more of the
following:
 Previous surgical diagnosis of endometriosis
 Pregnant
 Deep endometriosis or ovarian endometrioma on
imaging or at laparoscopy
 Ovarian cyst requiring surgical management
 Peritoneal ‘pockets’ only noted at laparoscopy
Interventions
Participants will be randomised to diagnostic laparos-
copy alone or surgical removal of SPE. The operating
surgeon can choose to remove the endometriosis either
by excision, ablation or a combination of the two at their
own discretion. All surgeons will be asked to insert two
5mm lateral wall ports in addition to the 10mm umbil-
ical port. One lateral wall 5 mm port is always required
for a diagnostic laparoscopy. A second lateral wall port
is often required to remove endometriosis lesions. Two
5mm ports will therefore be inserted in order to main-
tain patient blinding. All participants consented to the
study will be informed of other options for the manage-
ment of endometriosis-associated pain available to them
throughout the trial, as part of routine clinical care, in-
cluding analgesics, ovarian suppressive drugs, neuromo-
dulators and physical and psychological therapy.
Primary outcome
The proportion of eligible women, who agree to ran-
domisation. If the upper limit of the 95% confidence
interval of the proportion of eligible women who agree
to randomisation is not less than 40% then this will be
deemed an acceptable recruitment rate to proceed to a
definitive trial.
Secondary outcomes
 The reasons why women decline participation
 The proportion of women undergoing diagnostic
laparoscopy who go on to be diagnosed with SPE
 Intraoperative and postoperative complications
 Pelvic pain and quality of life
 Need for analgesia, hormonal treatment, and/or
neuromodulators after laparoscopy (immediate post-
operative period and longer term)
 The proportion of completed trial questionnaires
 Maintenance of blinding
 Adverse events (as reported by the participants)
 Acceptability of the trial
Participant enrolment
Participants will be recruited from gynaecology out-
patient departments following a clinical decision to per-
form a diagnostic laparoscopy for the investigation of
chronic pelvic pain. Potentially eligible women will be
asked by their attending clinician if they are happy to
meet with a member of the clinical research team. If
they agree, the women will then be given a patient infor-
mation sheet and the opportunity to discuss the trial. A
letter of invitation may also be sent to potential partici-
pants who have been referred to the research team from
the women’s direct clinical care team. Due to the
COVID-19 pandemic, initial contact by the research
team was widened to include contact by telephone. Con-
sent will only be taken later once the patient has had
ample time, of at least 24 h, to read the patient informa-
tion sheet. A further appointment will be arranged for
the participant to come for this visit. Those patients ini-
tially contacted by telephone have the option to attend
the hospital to discuss the trial and provide written in-
formed consent or provide informed consent verbally
over the telephone. All participants will be asked to re-
confirm consent on the day of laparoscopy and will be
asked to sign the study consent form before any research
activities are carried out.
For those not interested in the trial, we will ask them
to sign a separate short consent form agreeing for us to
keep their age, ethnicity, part of their postcode (to calcu-
late DEPCAT score), duration of pain, and reason for
not participating so that we can look at the demograph-
ics of those participants who decline, which will help
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inform a future larger trial. This short consent may take
place in less than 24 h as this may take place in a clinic
setting and will reduce the burden of further contact on
the participant. If eligible participants were not
approached, we will ask the attending clinician to docu-
ment their reasoning for this. All data will be recorded
on a case report form and transferred to a secure data-
base. The diagnosis at laparoscopy will be established for
all eligible women for the duration of the trial to estab-
lish the true incidence of SPE in isolation.
Sample size
The emphasis in this study is to establish feasibility, not
statistical significance. This study is designed primarily to
explore recruitment rates, and we will aim to recruit as
many women as possible over a 9-month period. We esti-
mate that we will recruit ~ 2–3 women per month per
centre and will aim to recruit up to 90 women. Ninety par-
ticipants would be able to give a half width of the 95% con-
fidence interval of +/− 6.4% around a 40% recruitment rate.
Randomisation
Eligibility will be confirmed by the clinical research team
at the time of laparoscopy following a finding of SPE
only. Participants will then be randomised by the clinical
research team in a 1:1 ratio to either diagnostic laparos-
copy alone or to concurrent surgical removal (ablation/
excision) by simple randomisation using a computer-
generated random number list provided independently
by the Edinburgh Clinical Trials Unit (ECTU). As ran-
domisation takes place intra-operatively, it will be a fast,
simple procedure in theatre via a web-based system, or
via a telephone call to the trial management team who
will use the computer system on their behalf.
Blinding
At the time of consent, the participant will be reminded that
they will be given a diagnosis post-operatively of the findings
at the time of laparoscopy but will not be told if surgical re-
moval of endometriosis was carried out. They will be told
that the details of whether the endometriosis was removed,
or not, will not be disclosed to their GP. Details of trial par-
ticipation and diagnosis will be disclosed to the GP as well
as any recommended treatment from their attending phys-
ician. There will be a process by which they can be un-
blinded at their request prior to the formal unblinding
process at 12months. Details of the extent and type of re-
moval (ablation, excision or both) will be recorded. All of
the surgical findings and any surgical procedures to remove
the endometriosis will be available in the medical notes and
there will be information about the participation in the trial
and the importance of maintaining the participant blind. At
the end of participation, the participants’ GPs will be in-
formed if surgical removal was performed.
Data collection tools
Our ‘trial questionnaire’ comprises of a range of validated
patient-reported questionnaires, collected pre-operatively
and then at 3, 6 and 12months’ post-surgery (minimum
data collection timepoints). The baseline and follow-up
trial questionnaires will differ in that as follows:
1. The baseline questionnaire contains text prior to
the EHP-30 as follows “This questionnaire asks
about symptoms due to endometriosis. We realise
that you do not know whether or not you have
endometriosis so please try and ignore the refer-
ences to endometriosis and simply answer the ques-
tions focusing on the symptoms.”
2. The questions in the MYMOP2 questionnaire have
been adapted in the follow-up questionnaires to ac-
count for the fact that the participant needs to re-
member how they answered this questionnaire at
baseline.
The ‘trial questionnaire’ will include the following:
 Endometriosis Health Profile-30 (EHP-30) [11]
 Rome IV Criteria [12]
 Pelvic Pain and Urgency/Frequency Patient (PUF)
Symptom Scale [13]
 painDETECT™ [14]
 Brief Fatigue Inventory (BFI) [15]
 Pain Catastrophising Questionnaire (PCQ) [16]
 Fibromyalgia Scale (FS) [17]
 Measure Yourself Medical Outcome Profile 2
(MYMOP 2) [18]
 Working Productivity and Activity Impairment
Questionnaire (WPAIQ) [19]
 EuroQol 5 Dimensions 5 Level Questionnaire (EQ-
5D-5L) [20]
 Capability Questionnaire (ICECAP-A) [21]
At 3, 6 and 12months post-randomisation, partici-
pants will be asked questions (‘outcome questionnaire’)
about analgesic use, hormonal medication, pregnancy,
and the use of healthcare services. At 3 months post-
surgery, participants will also be asked to complete an
additional questionnaire (‘acceptability’) that will include
questions about the questionnaires and the acceptability
of trial participation. This will be via a telephone call
with a member of the research team.
Details of surgical findings and surgical removal of
endometriosis
Following laparoscopy, the surgeon will be asked to
complete a surgical case report form (SCRF) detailing in-
formation from the operation:
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 Surgeon’s name(s)
 Extent of endometriosis
 Duration of surgery
 Concurrent intra-uterine system (IUS) insertion
 Intraoperative complications (bowel injury, ureteric
injury, bladder injury, vascular injury and reverting
to laparotomy)
If allocated to surgical removal of endometriosis:
 Type of removal will be recorded (excision, ablation
or both).
 Subjective assessment of whether or not complete
removal was achieved.
In addition, the SCRF includes a specific set of pre-
determined photographs. For the diagnostic laparoscopy,
this is a standard panel of photographs of the pelvis,
which includes the utero-vesical fold, Pouch of Douglas
and right and left ovarian fossa. If allocated to surgical
removal, the approach (ablation, excision or a combin-
ation) will be documented; as well an assessment of the
adequacy of removal and photographs of the areas after
the endometriosis has been removed. Two independent
clinicians will assess these images, blind to initial classifi-
cation, to reduce the likelihood of misclassification.
Post-operative complications
A post-operative complications form (part of the CRF) will
be completed detailing complication up to 30 days post-
operation. This will be completed by the clinical research
team, utilised information gained by a phone call to the
participant and correlated with the participant’s hospital
record. Specific complications include urinary retention,
unintended overnight stay, haemorrhage, transfusion pel-
vic haematoma, visceral injury (bowel, bladder, ureteric),
infection (urinary, chest, wound, pelvic abscess, other),
venous thromboembolism, fistula, hernia, return to the-
atre, readmission, ITU admission and death.
Unblinding
An unblinding facility will be available on the database.
If a clinician would like to unblind a participant (e.g. at
the participant’s request), they will need to contact the
research team who will be able to tell them which arm
of the study they were in. Participants will be given the
option to be unblinded at the end of the trial.
Adverse events
Participants will be asked about the occurrence of ad-
verse events related to their surgery and related medical
therapies, which will be recorded in the post-operative
CRF at 30 days.
Data analysis
Analysis of the quantitative data will largely consist of
descriptive statistics and comparison between the two
groups. Throughout, we will summarise continuous vari-
ables using the mean, standard deviation, median, lower
quartile, upper quartile, minimum, and maximum
values. We will report categorical variables using the fre-
quency and percentage for each category. Baseline
demographic and clinical data will be summarised by
study arm and overall. The feasibility outcomes (propor-
tion of eligible women who agree to randomisation, the
proportion who decline participation, the proportion
who are diagnosed with SPE and the type of surgical re-
moval) will be analysed by calculating the proportion
and its exact binomial 95% confidence interval. Clinical
and patient outcomes will be summarised by study arm
and overall and reported as a difference between study
arms. The acceptability of trial participation, proposed
methods of recruitment, randomisation, and assessment
tools will be assessed quantitatively using the acceptabil-
ity questionnaire to explore comparisons between the
two groups and will be reported as estimates of differ-
ence. The variability in the EHP-30 pain domain score
and other patient-reported outcome scores will be used
to inform the sample size calculation for the full trial.
We will qualitatively review the acceptability question-
naire and determine the nature and number of un-
answered questions within the clinical questionnaire to
refine our assessment tools for the future definitive trial.
Data handling, storage and archiving
A log with the participants’ name and date of birth will be
kept along with their unique study number in a separate
file. All the data generated from the study will be stored in
a pseudo-anonymised form in a bespoke database, which
will also be password protected. Only anonymised informa-
tion will be stored on this, and participants will only be
identifiable by their study number. All paperwork will be
kept in a locked filing cabinet in a locked office. All data
will be stored on a university server on a password-
protected computer with access limited to the research
team, in accordance with NHS and University of Edinburgh
guidelines, and in accordance with the Data Protection Act.
All study documentation will be kept for a minimum of 5
years from the protocol-defined end of study point. When
the minimum retention period has elapsed, study docu-
mentation will not be destroyed without permission from
the Sponsors (NHS Lothian and The University of Edin-
burgh). The statistical analysis plan will be written prior to
unblinding but the final analysis will be done unblinded.
Data monitoring
No data monitoring committee will be convened for this
small feasibility study as all care is standard care or less.
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The trial management group will ensure that any ad-
verse events are reported in a timely manner to the
sponsor for review.
Trial sponsors
The trial is co-sponsored by the University of Edinburgh
and NHS Lothian.
Ethical approval
Ethical approval has been obtained from the East of
Scotland Ethics Committee (NHREC 19/ES/0079).
Dissemination
Data will be published in peer-reviewed journals and
presented at international conferences. The clinical
study report will be used for publication and presenta-
tion at scientific meetings. We will make the information
obtained from the study available to the public through
national and international bodies, e.g. Endometriosis UK
and Endometriosis.org.
Discussion
We recognise that there may be difficulties in recruiting
to a definitive randomised controlled trial (RCT) to assess
the effectiveness of surgery for the painful symptoms asso-
ciated with superficial peritoneal endometriosis (SPE). We
have therefore designed this study to assess the feasibility
of recruitment and to generate adequate data to meaning-
fully reduce uncertainties in other important aspects of
the future trial.
A systematic review of surgical RCTs with a placebo
arm found that slow recruitment, due to difficulties find-
ing eligible patients (and clinicians) who would agree to
participate, was the major barrier to successful trial com-
pletion [22]. Patients and clinicians may have inherent
beliefs and preferences about surgery as an intervention,
which might affect their willingness to participate in a
surgical trial with a placebo arm. In this study, we are in-
vestigating a surgical procedure that is already widely ac-
cepted and available, despite an absence of high-quality
evidence supporting its use. We conducted a national
online survey of clinicians who manage women with
endometriosis in 2017. After excluding those that did
not perform laparoscopies, we had 88 responses. When
asked to judge the strength of the evidence for ablation
and excision for endometriosis, where zero is very weak
and 10 very strong, the average weights were 5.9 and 4.3,
respectively. Furthermore, 81% of surgeons consider a
trial to be required, and 73% are willing to participate.
We also conducted an online survey targeting women
with endometriosis with promotion from Endometriosis
UK, the Endometriosis Association of Ireland, and Endo-
metriosis.org. We received responses from 1218 women,
of whom 98.8% had endometriosis, and 83% had their
endometriosis treated surgically. When asked whether
they would consider taking part in the proposed defini-
tive trial, 20% ‘definitely would’, 26% ‘would likely par-
ticipate’, and 17% ‘did not know’.
To improve recruitment, we aim to identify and en-
gage with all relevant stakeholders and to develop and
test tailored messages and educational materials [23, 24].
We will involve patient representatives and members of
the relevant professional surgical societies throughout
the study to help increase buy-in of the trial by
highlighting the importance of the research question and
the worthiness of the placebo design.
A potential limitation (but also a strength) of our
study is the broad inclusion and exclusion criteria, which
we have produced in an attempt to reflect the true clin-
ical scenario of endometriosis. Our criteria do not take
into account pain intensity, do not exclude women with
non-reproductive comorbidities (e.g. irritable bowel syn-
drome, bladder pain syndrome) that could explain their
symptoms, and allow participants the use of concomi-
tant medications. We are aware that these characteristics
may increase variability in patient responsiveness to
treatment and consequently carry the risk of failing to
demonstrate treatment effect. We will therefore capture
this information in our study in the participants’ ques-
tionnaires to ensure informed interpretation of our re-
sults as well as aid in the planning of the future
definitive trial.
We have chosen data collection tools to assess the
core domains of pain, physical/emotional functioning
(including sleeping difficulties), improvement/satisfac-
tion with treatment, symptoms and adverse events, fol-
lowing advice from a pain medicine specialist and
clinical psychologist. These tools are in line with the
IMMPACT recommendations for chronic pain trials [25,
26]. We will assess the reliability and acceptability of
these data collection tools in order to refine our
methods for the subsequent RCT.
We acknowledge that blinding, whilst essential for an
objective reporting of pain by the women, presents add-
itional challenges. In our clinician survey, when surgeons
were asked whether they would be prepared to insert an
extra port (total of two 5mm ports in addition to the
camera port) at the time of surgery to blind women to
treatment allocation, 58% of surgeons agreed. We will
monitor the compliance with this extra measure in the
diagnostic laparoscopy only group, and survey the ac-
ceptability amongst the participants.
In summary, this study with embedded evaluation
of trial processes and collection of outcome data, will
allow us to undertake detailed feasibility work to in-
form a future large-scale trial in the important but
challenging area of surgery for endometriosis-
associated pain.
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